Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form - 19/12/14
, Rodney L. Dunn a, Martin G. Sanda d, Peter Chang e, Thomas K. Greenfield f, Mark S. Litwin g, John T. Wei athe
PROSTQA Consortium
Abstract |
Objective |
To establish a score threshold that constitutes a clinically relevant change for each domain of the Expanded Prostate Cancer Index Composite (EPIC) Short Form (EPIC-26). Although its use in clinical practice and clinical trials has increased worldwide, the clinical interpretation of this 26-item disease-specific patient-reported quality of life questionnaire for men with localized prostate cancer would be facilitated by characterization of score thresholds for clinically relevant change (the minimally important differences [MIDs]).
Methods |
We used distribution- and anchor-based approaches to establish the MID range for each EPIC-26 domain (urinary, sexual, bowel, and vitality/hormonal) based on a prospective multi-institutional cohort of 1201 men treated for prostate cancer between 2003 and 2006 and followed up for 3 years after treatment. For the anchor-based approach, we compared within-subject and between-subject score changes for each domain to an external “anchor” measure of overall cancer treatment satisfaction.
Results |
We found the bowel and vitality/hormonal domains to have the lowest MID range (a 4-6 point change should be considered clinically relevant), whereas the sexual domain had the greatest MID values (10-12). Urinary incontinence appeared to have a greater MID range (6-9) than the urinary irritation/obstruction domain (5-7).
Conclusion |
Using 2 independent approaches, we established the MIDs for each EPIC-26 domain. A definition of these MID values is essential for the researcher or clinician to understand when changes in symptom burden among prostate cancer survivors are clinically relevant.
Le texte complet de cet article est disponible en PDF.Plan
| A full list of authors “PROSTQA Consortium” is available in the Acknowledgments section. |
|
| Financial Disclosure: Ted A. Skolarus is supported by a VA HSR&D Career Development Award 2 (CDA 12-171). Martin Sanda receives research grants from National Institutes of Health, Prostate Cancer Foundation, and Movember. Peter Chang is supported by a grant from the Urology Care Foundation Research Scholar Program and Dornier Medtech entitled “Measuring Prostate Cancer Patient Reported Outcomes at the Point of Care.” Thomas K. Greenfield is supported by a National Institute on Alcohol Abuse and Alcoholism Center grant (P50 AA005595). PROSTQA Consortium is supported by National Institutes of Health grants R01 CA95662 and RC1 CA146596. The remaining authors declare that they have no relevant financial interests. |
Vol 85 - N° 1
P. 101-106 - janvier 2015 Retour au numéro
Article précédent
- Prediction of Long-term Other-cause Mortality in Men With Early-stage Prostate Cancer: Results From the Prostate Cancer Outcomes Study
- Timothy J. Daskivich, Kang-Hsien Fan, Tatsuki Koyama, Peter C. Albertsen, Michael Goodman, Ann S. Hamilton, Richard M. Hoffman, Janet L. Stanford, Antoinette M. Stroup, Mark S. Litwin, David F. Penson
- Editorial Comment
- Suzanne M. Miller
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?